Drug Profile
Research programme: targeted radioconjugates - ITM Group/Navigo Proteins
Alternative Names: 177Lu-DOTA-Affilin; 68Ga-DOTA-Affilin; n.c.a. 177Lu-DOTA-AffilinLatest Information Update: 28 Aug 2023
Price :
$50
*
At a glance
- Originator Isotopen Technologien Munchens; Navigo Proteins
- Class Radiopharmaceuticals
- Mechanism of Action DNA modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Aug 2023 No recent reports of development identified for preclinical development in Solid-tumours in Germany (Parenteral)
- 02 Dec 2021 Navigo Proteins and ITM group entered into an R&D agreement to develop a fibroblast activation protein (FAP)-targeted radiopharmaceutical program for the treatment of solid tumors
- 07 Oct 2021 Navigo Proteins and ITM group announce extension of collaboration agreement for development of radio conjugates for the treatment of cancer